@Article{,
AUTHOR = {Susan S. Garfield, Meghan B. Gavaghan, Shannon O. Armstrong, J. Stephen Jones},
TITLE = {The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States  projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {20},
YEAR = {2013},
NUMBER = {2},
PAGES = {6682--6689},
URL = {http://www.techscience.com/CJU/v20n2/61623},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Several studies, including the recently published phase III study by Stenzl and colleagues, have demonstrated that hexaminolevulinate hydrochloride, when used with blue light fluorescence cystoscopy, improves detection of non-muscle invasive bladder tumors compared to white light cystoscopy and transurethral resection of bladder tumors (TURB) alone.<br/>
<b>Materials and methods:</b> The objective of this study was to conduct a detailed assessment of the cost-effectiveness of using hexaminolevulinate hydrochloride with blue light cystoscopy as an adjunct to white light versus white light cystoscopy alone at the time of initial TURB in the United States. A probabilistic decision tree model, using TreeAge Pro 2011 software, was developed using base case scenario cost and utility estimates.<br/>
<b>Results:</b> Incorporation of hexaminolevulinate hydrochloride into diagnostic cystoscopy results in lower costs over 5 years ($25,921) as compared to those patients who initially receive white light cystoscopy ($30,581). Those patients who initially receive hexaminolevulinate hydrochloride blue light TURB also experience a lower overall cancer burden.<br/>
<b>Conclusions:</b> Hexaminolevulinate hydrochloride may be cost-effective when used at first TURB for patients with suspected new or recurrent non-muscle invasive bladder cancer.},
DOI = {}
}